Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Shaji Kumar, MD, on Stem Cell Transplant and First-Line Multiple Myeloma Treatment With Bortezomib, Lenalidomide, and Dexamethasone

Posted: Friday, May 29, 2020

Shaji Kumar, MD, of the Mayo Clinic, discusses findings from the ENDURANCE trial and how transplant fits in the overall treatment plan for patients with newly diagnosed standard- or intermediate-risk multiple myeloma.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.